BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12625033)

  • 1. DU-127090 Solvay/H Lundbeck.
    Wolf W
    Curr Opin Investig Drugs; 2003 Jan; 4(1):72-6. PubMed ID: 12625033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sumanirole Pharmacia.
    de Paulis T
    Curr Opin Investig Drugs; 2003 Jan; 4(1):77-82. PubMed ID: 12625034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of cariprazine.
    Stahl SM
    CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
    Norman MH; Rigdon GC; Hall WR; Navas F
    J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repinotan Bayer.
    Lutsep HL
    Curr Opin Investig Drugs; 2002 Jun; 3(6):924-7. PubMed ID: 12137415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecule of the month. Bifeprunox mesilate.
    Drug News Perspect; 2005 Oct; 18(8):523. PubMed ID: 16391722
    [No Abstract]   [Full Text] [Related]  

  • 8. SLV-308. Solvay.
    Wolf WA
    Curr Opin Investig Drugs; 2003 Jul; 4(7):878-82. PubMed ID: 14619412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siramesine H Lundbeck.
    Heading C
    Curr Opin Investig Drugs; 2001 Feb; 2(2):266-70. PubMed ID: 11816842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
    Fitzgerald PB
    Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donitriptan (Pierre Fabre).
    Dukat M
    Curr Opin Investig Drugs; 2001 Mar; 2(3):415-8. PubMed ID: 11575714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of anxiolytics and their therapeutic use].
    Tada K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):608-11. PubMed ID: 12877061
    [No Abstract]   [Full Text] [Related]  

  • 15. ACS chemical neuroscience molecule spotlight on Fanapt.
    Hopkins CR
    ACS Chem Neurosci; 2010 Jun; 1(6):410. PubMed ID: 22778835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aripiprazol. An atypical neuroleptic with exceptional mechanisms of action] ].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2004 Nov; 27(11):364-7. PubMed ID: 15566230
    [No Abstract]   [Full Text] [Related]  

  • 18. Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s.
    Dupuis DS; Mannoury la Cour C; Chaput C; Verrièle L; Lavielle G; Millan MJ
    Eur J Pharmacol; 2008 Jul; 588(2-3):170-7. PubMed ID: 18511034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.